- Home
- NTRB vs BYSI Comparison
NTRB vs BYSI Comparison
Compare NTRB & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- BYSI
- Stock Information
- Founded
- NTRB 2016
- BYSI 2010
- Country
- NTRB United States
- BYSI United States
- Employees
- NTRB N/A
- BYSI N/A
- Industry
- NTRB Industrial Specialties
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- BYSI Health Care
- Exchange
- NTRB Nasdaq
- BYSI Nasdaq
- Market Cap
- NTRB 59.1M
- BYSI 67.3M
- IPO Year
- NTRB N/A
- BYSI 2017
- Fundamental
- Price
- NTRB $7.75
- BYSI $1.73
- Analyst Decision
- NTRB Buy
- BYSI
- Analyst Count
- NTRB 1
- BYSI 0
- Target Price
- NTRB $13.00
- BYSI N/A
- AVG Volume (30 Days)
- NTRB 28.3K
- BYSI 20.0K
- Earning Date
- NTRB 05-30-2025
- BYSI 05-12-2025
- Dividend Yield
- NTRB N/A
- BYSI N/A
- EPS Growth
- NTRB N/A
- BYSI N/A
- EPS
- NTRB N/A
- BYSI N/A
- Revenue
- NTRB $2,398,437.00
- BYSI N/A
- Revenue This Year
- NTRB $571.50
- BYSI N/A
- Revenue Next Year
- NTRB $577.37
- BYSI N/A
- P/E Ratio
- NTRB N/A
- BYSI N/A
- Revenue Growth
- NTRB 18.92
- BYSI N/A
- 52 Week Low
- NTRB $3.72
- BYSI $0.98
- 52 Week High
- NTRB $11.78
- BYSI $2.97
- Technical
- Relative Strength Index (RSI)
- NTRB 72.87
- BYSI 54.43
- Support Level
- NTRB $6.03
- BYSI $1.62
- Resistance Level
- NTRB $5.84
- BYSI $1.77
- Average True Range (ATR)
- NTRB 0.47
- BYSI 0.08
- MACD
- NTRB 0.17
- BYSI -0.00
- Stochastic Oscillator
- NTRB 69.14
- BYSI 70.53
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.